The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer

Annals of Oncology

Volumn 16, Issue 8, 2005, Pages 1334-1342

  Zhang, X T ^a   Li, L Y ^a   Mu, X L ^a   Cui, Q C ^a   Chang, X Y ^a   Song, W ^a   Wang, S L ^a   Wang, M Z ^a   Zhong, W ^a   Zhang, L ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

EGFR mutation; Gefitinib; Non small cell lung cancer; p EGFR; Predictive marker; Targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; LIVER ENZYME; PLATINUM DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CHINESE; CLINICAL TRIAL; CORRELATION ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRY SKIN; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NAUSEA; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 23844517762     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi340     Document Type: Article

References (26)

1. Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trails. BMJ 1995; 311: 899-909.
2. Schill J. Current standards of care in small-cell and non-small-cell lung cancer. Oncology 2001; 61: 3-13.
3. Haura EB. Treatment of advanced non-small-cell lung cancer: A review of current randomized clinical trials and an examination of emerging therapies. Cancer Control 2001; 8: 326-336.
4. Moscatello DK, Holgado-Madruga M, Godwin AK et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995; 55: 5536-5539.
5. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82: 241-250.
6. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7 (Suppl 4): 2-8.
7. Ranson M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J. Clin Oncol 2002; 20: 2240-2250.
8. Baselga J, Rischin D, Ranson M et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20: 4292-4302.
9. Fukuoka M, Yano S, Giaccone G. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-2246.
10. Kris MG, Natale RB, Herst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor tyrosine kinase, in symptomatic patients with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
11. Bailey R, Kris M, Wolf M et al. Gefitinib ('Iressa', ZD 1839) monotherapy for pretreated advanced non-small cell lung cancer in IDEAL 1 and 2: Tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone. Lung Cancer 2003; 41 (Suppl 571): (Abstr).
12. Paez JG, Janne PA, Lee JC et al. EGFR mutation in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
13. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
14. Response evaluation criteria in solid tumors (RECIST) quick reference. Available online at: http://www.nci.nih.gov/bip/RECIST.htm.
15. Cancer Therapy Evaluation Program, Common Toxicity Criteria, Version 2.0, DCTD, NCI, NIH, DHHS. Available online at: http://ctep.cancer.gov.
16. Shepheral FA, Dancey J, Ramlan R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
17. De Marinis F, De Petris L. Pemetrexed in second-line treatment of non-small-cell lung cancer. Oncology (Huntingt) 2004; 18 (Suppl 8): 38-42.
18. New drug to treat most common lung cancer. FDA Consum 2005; 39: 3.
19. Cohen MH, Williams GA, Sridhara R et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003; 8: 303-306.
20. Nakagawa K, Tamura T, Negoro S et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003; 14: 922-930.
21. Inoue A, Saijo Y, Maemondo M, Gomi K et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003; 361: 137-139.
22. Bailey LR, Kris M, Wolf M et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gifitinib (Iressa, ZD 1839) monotherapy for pretreated advanced non-smallcell lung cancer: IDEAL 1 and 2 (abstract no. LB-170). Proceedings of the 94th Annual Meeting of the American Association for Cancer Research. Washington, DC; July 2003. Philadelphia, PA: AACR, 1362.
23. Cappuzzo F, Gregorc V, Rossi E et al. Gefitinib in pretreated non-small cell lung cancer (NSCLC): Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 2003; 21: 2658-2663.
24. Han S-W, Hwang PG, Chung DH et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD 1839) in chemotherapy-resistant non small cell lung cancer. Int J Cancer 2005; 113: 109-115.
25. Cappuzzo F, Magrini E, Cereoli GL et al. Akt phosphorylation and gefitinib effficacy in patients with advanced non-small cell lung cancer. Int J Cancer 2004; 96: 1133-1141.
26. Huang SF, Liu HP, Li LH et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancer related to gefitinib responsiveness in Taiwan. Clin Cancer Research 2004; 10: 8195-8233.